Literature DB >> 35105447

Association between uterine fibroids and antimüllerian hormone concentrations among African American women.

Lia A Bernardi1, Anne Waldo2, Veronica J Berrocal3, Lauren A Wise4, Erica E Marsh5.   

Abstract

OBJECTIVE: To evaluate the extent to which uterine fibroids are associated with antimüllerian hormone (AMH) concentrations.
DESIGN: Cross-sectional study.
SETTING: Baseline data from the Study of the Environment, Lifestyle, and Fibroids, which is a 5-year longitudinal study of African American women. PATIENT(S): A total of 1,643 women aged 23-35 years without a known history of fibroids. EXPOSURE: Fibroid presence. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): The primary outcome was percent difference in the mean AMH concentration between participants with fibroids and those without fibroids. The secondary outcomes were percent differences in the mean AMH concentrations in participants with different numbers, sizes, types, and positions of fibroids and the percent difference in the mean AMH concentration in participants with different uterine volumes. RESULT(S): At least 1 fibroid was identified on ultrasound in 362 (22%) participants. There was a small difference in the mean AMH concentrations in participants with fibroids (age-adjusted model: -4.6%, 95% confidence interval (CI): -14.5% to 6.5%; multivariable model: -4.6%, 95% CI: -14.4% to 6.3%). The mean AMH concentrations were found to decrease with increasing fibroid number. Although differences in AMH concentrations were not statistically significant, compared with no fibroids, the mean percent differences in AMH concentrations for 1, 2-3, and ≥4 fibroids were -1.2% (95% CI: -13.2% to 12.5%), -7.1% (95% CI: -23.3% to 12.5%), and -17.5% (95% CI: -38.2% to 10.0%), respectively. There were no consistent associations between AMH concentrations and fibroid location, size, or uterine volume. CONCLUSION(S): The presence of fibroids was not materially associated with AMH concentrations. Other than a monotonic inverse relationship between fibroid number and AMH concentrations, no other fibroid characteristics were consistently or appreciably associated, although associations were imprecise.
Copyright © 2021 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimüllerian hormone; ovarian reserve; uterine fibroids; uterine leiomyomas

Mesh:

Substances:

Year:  2022        PMID: 35105447      PMCID: PMC8983564          DOI: 10.1016/j.fertnstert.2021.12.019

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  24 in total

1.  Anti Müllerian hormone levels before and after uterine artery embolization: A preliminary report.

Authors:  Bruce Mclucas; William D Voorhees; Katherine Jane C Chua
Journal:  Minim Invasive Ther Allied Technol       Date:  2015-03-01       Impact factor: 2.442

Review 2.  Uterine fibroids.

Authors:  Serdar E Bulun
Journal:  N Engl J Med       Date:  2013-10-03       Impact factor: 91.245

Review 3.  Testing and interpreting measures of ovarian reserve: a committee opinion.

Authors: 
Journal:  Fertil Steril       Date:  2020-12       Impact factor: 7.329

4.  Early follicular serum müllerian-inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles.

Authors:  David B Seifer; David T MacLaughlin; Benjamin P Christian; Bo Feng; Robert M Shelden
Journal:  Fertil Steril       Date:  2002-03       Impact factor: 7.329

5.  The effects of uterine artery embolization on ovarian reserve.

Authors:  Chang-Woon Kim; Haeng Seon Shim; Hong Jang; Yun Gyu Song
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2016-09-23       Impact factor: 2.435

6.  Racial differences in fibroid prevalence and ultrasound findings in asymptomatic young women (18-30 years old): a pilot study.

Authors:  Erica E Marsh; Geraldine E Ekpo; Eden R Cardozo; Maureen Brocks; Tanaka Dune; Leeber S Cohen
Journal:  Fertil Steril       Date:  2013-03-15       Impact factor: 7.329

7.  A Prospective, Ultrasound-Based Study to Evaluate Risk Factors for Uterine Fibroid Incidence and Growth: Methods and Results of Recruitment.

Authors:  Donna D Baird; Quaker E Harmon; Kristen Upson; Kristen R Moore; Christie Barker-Cummings; Susan Baker; Tracy Cooper; Ganesa Wegienka
Journal:  J Womens Health (Larchmt)       Date:  2015-09-03       Impact factor: 2.681

8.  Novel correlates between antimüllerian hormone and menstrual cycle characteristics in African-American women (23-35 years-old).

Authors:  Erica E Marsh; Lia A Bernardi; Marissa L Steinberg; Peter J de Chavez; Jenny A Visser; Mercedes R Carnethon; Donna D Baird
Journal:  Fertil Steril       Date:  2016-04-23       Impact factor: 7.329

9.  The assessment of benign uterine tumor vascularization by transvaginal color Doppler.

Authors:  A Kurjak; S Kupesic-Urek; D Miric
Journal:  Ultrasound Med Biol       Date:  1992       Impact factor: 2.998

Review 10.  The physiology and clinical utility of anti-Mullerian hormone in women.

Authors:  Didier Dewailly; Claus Yding Andersen; Adam Balen; Frank Broekmans; Nafi Dilaver; Renato Fanchin; Georg Griesinger; Tom W Kelsey; Antonio La Marca; Cornelius Lambalk; Helen Mason; Scott M Nelson; Jenny A Visser; W Hamish Wallace; Richard A Anderson
Journal:  Hum Reprod Update       Date:  2014-01-14       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.